Moderna Stock Rises on Platform Validation as GSK Pushes Rival Flu mRNA to Phase III

Moderna stock jumped about 6% midday after GSK moved its rival mRNA influenza vaccine to Phase III, a development investors view as platform validation for mRNA tech rather than direct competition to Moderna's mFlusvia, which recently received FDA approval. The move underscores the market’s focus on the broader potential of mRNA platforms (including Moderna’s melanoma program with MRK) rather than near-term vaccine revenue, with analysts cautioning that sustained upside hinges on broad solid-tumor success and continued adoption amid a backdrop of policy and financing developments for the modality.